Phase II trial of the novel combination, decitabine, venetoclax, and ponatinib achieved bone marrow remission in 80% of ...

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the approval of the Investigational New ...

For most people, the word cancer implies that there’s a tumor or mass growing somewhere in the body. However, contrary to ...

“‘Hispanic’ is a very diverse group of people. It’s an ethnicity ... Guzman then referenced a study from 2018 that had major ...

accounting for about 80% of acute leukemia in adults. The risk of developing AML increases with age and is more common in middle-aged and elderly people. AML is also not uncommon in individuals ...

Before receiving treatment for acute myeloid leukemia, I made it a point to take advantage of all the resources that were ...

The bioengineering company Ossium Health has created a new program that offers deep-frozen bone marrow from deceased organ ...

The community unites to host a music festival to fundraise for Dylan René, 6, and her father, Josiah Menard who are facing ...

have demonstrated potential to extend survival outcomes for people with relapsed and refractory acute myeloid leukemia. Actinium plans to advance Iomab-B for other blood cancers and next generation ...